Literature DB >> 8008410

Spinal cord stimulation in Belgium: a nation-wide survey on the incidence, indications and therapeutic efficacy by the health insurer.

R C Kupers1, R Van den Oever, B Van Houdenhove, W Vanmechelen, B Hepp, B Nuttin, J M Gybels.   

Abstract

The present report describes a nation-wide survey on the incidence, the indications and the efficacy of spinal cord stimulation (SCS), as assessed by the Belgian health authorities. The direct motive for this survey was the rapidly growing expenditures resulting from the increasing use of SCS. Between 1983 and 1992, nearly 700 SCS devices were implanted for a population of less than 10 million inhabitants. The most common indication for SCS was failed back survey (61.4%). Whereas SCS was initially only performed in university teaching hospitals, it is now also widely practised in general hospitals. In 3 studies, the efficacy of SCS was assessed. In a first study, success was defined in terms of resumption of professional activities. After a mean follow-up of more than 1 year, less than 5% of the 147 patients treated with SCS had returned to work. A second study investigated the subjective evaluation of the therapy by the patient. Seventy patients with a mean follow-up of 3.5 years were studied. In 52% of the patients, the effect of SCS was judged as good to very good. Men scored better than women. In addition, the results obtained in the teaching hospitals were significantly better than those obtained in general hospitals. In a third study, the impact of psychiatric screening on patient selection was evaluated. Of the 100 candidates, 36 were withheld from implantation with a SCS device because of psychiatric contra-indications. Patients who had received a positive psychiatric advice showed a significantly better therapeutic outcome than patients for whom the psychiatrist had made reservations.

Entities:  

Mesh:

Year:  1994        PMID: 8008410     DOI: 10.1016/0304-3959(94)90096-5

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  7 in total

Review 1.  Spinal cord stimulation for the treatment of angina and peripheral vascular disease.

Authors:  Timothy R Deer
Journal:  Curr Pain Headache Rep       Date:  2009-02

2.  A DEMONSTRATION OF A PRESURGICAL BEHAVIORAL MEDICINE EVALUATION FOR CATEGORIZING PATIENTS FOR IMPLANTABLE THERAPIES: A PRELIMINARY STUDY.

Authors:  Kimberly Gardner Schocket; Robert J Gatchel; Anna Wright Stowell; Martin Deschner; Richard Robinson; Leland Lou; Tony Whitworth; Dana Bernstein
Journal:  Neuromodulation       Date:  2008-10-08

3.  Outcomes of spinal cord stimulation: patient validation.

Authors:  Valerie C Anderson; Christina Carlson; Deborah Shatin
Journal:  Neuromodulation       Date:  2001-01

4.  A multicenter real-world review of 10 kHz SCS outcomes for treatment of chronic trunk and/or limb pain.

Authors:  Thomas Stauss; Faycal El Majdoub; Dawood Sayed; Gernot Surges; William S Rosenberg; Leonardo Kapural; Richard Bundschu; Abdul Lalkhen; Nileshkumar Patel; Bradford Gliner; Jeyakumar Subbaroyan; Anand Rotte; Deborah R Edgar; Martin Bettag; Mohammad Maarouf
Journal:  Ann Clin Transl Neurol       Date:  2019-01-22       Impact factor: 4.511

5.  Clinical Outcomes after Spinal Cord Stimulation According to Pain Characteristics.

Authors:  Jong-Ho Ha; Ryoong Huh; Shin-Gyeom Kim; Soo-Bin Im; Je Hoon Jeong; Sun-Chul Hwang; Dong-Seong Shin; Bum-Tae Kim; Moonyoung Chung
Journal:  J Korean Neurosurg Soc       Date:  2022-01-04

6.  Intracranial somatosensory responses with direct spinal cord stimulation in anesthetized sheep.

Authors:  Oliver E Flouty; Hiroyuki Oya; Hiroto Kawasaki; Chandan G Reddy; Douglas C Fredericks; Katherine N Gibson-Corley; Nicholas D Jeffery; George T Gillies; Matthew A Howard
Journal:  PLoS One       Date:  2013-02-15       Impact factor: 3.240

Review 7.  Pain relief and improvement in quality of life with 10 kHz SCS therapy: Summary of clinical evidence.

Authors:  Dawood Sayed; Jan Willem Kallewaard; Anand Rotte; Jessica Jameson; David Caraway
Journal:  CNS Neurosci Ther       Date:  2020-02-22       Impact factor: 5.243

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.